Cargando…
RIPK2: a promising target for cancer treatment
As an essential mediator of inflammation and innate immunity, the receptor-interacting serine/threonine-protein kinase-2 (RIPK2) is responsible for transducing signaling downstream of the intracellular peptidoglycan sensors nucleotide oligomerization domain (NOD)-like receptors 1 and 2 (NOD1/2), whi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266216/ https://www.ncbi.nlm.nih.gov/pubmed/37324457 http://dx.doi.org/10.3389/fphar.2023.1192970 |
_version_ | 1785058700946309120 |
---|---|
author | You, Jieqiong Wang, Ying Chen, Haifeng Jin, Fang |
author_facet | You, Jieqiong Wang, Ying Chen, Haifeng Jin, Fang |
author_sort | You, Jieqiong |
collection | PubMed |
description | As an essential mediator of inflammation and innate immunity, the receptor-interacting serine/threonine-protein kinase-2 (RIPK2) is responsible for transducing signaling downstream of the intracellular peptidoglycan sensors nucleotide oligomerization domain (NOD)-like receptors 1 and 2 (NOD1/2), which will further activate nuclear factor kappa-B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, leading to the transcription activation of pro-inflammatory cytokines and productive inflammatory response. Thus, the NOD2-RIPK2 signaling pathway has attracted extensive attention due to its significant role in numerous autoimmune diseases, making pharmacologic RIPK2 inhibition a promising strategy, but little is known about its role outside the immune system. Recently, RIPK2 has been related to tumorigenesis and malignant progression for which there is an urgent need for targeted therapies. Herein, we would like to evaluate the feasibility of RIPK2 being the anti-tumor drug target and summarize the research progress of RIPK2 inhibitors. More importantly, following the above contents, we will analyze the possibility of applying small molecule RIPK2 inhibitors to anti-tumor therapy. |
format | Online Article Text |
id | pubmed-10266216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102662162023-06-15 RIPK2: a promising target for cancer treatment You, Jieqiong Wang, Ying Chen, Haifeng Jin, Fang Front Pharmacol Pharmacology As an essential mediator of inflammation and innate immunity, the receptor-interacting serine/threonine-protein kinase-2 (RIPK2) is responsible for transducing signaling downstream of the intracellular peptidoglycan sensors nucleotide oligomerization domain (NOD)-like receptors 1 and 2 (NOD1/2), which will further activate nuclear factor kappa-B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, leading to the transcription activation of pro-inflammatory cytokines and productive inflammatory response. Thus, the NOD2-RIPK2 signaling pathway has attracted extensive attention due to its significant role in numerous autoimmune diseases, making pharmacologic RIPK2 inhibition a promising strategy, but little is known about its role outside the immune system. Recently, RIPK2 has been related to tumorigenesis and malignant progression for which there is an urgent need for targeted therapies. Herein, we would like to evaluate the feasibility of RIPK2 being the anti-tumor drug target and summarize the research progress of RIPK2 inhibitors. More importantly, following the above contents, we will analyze the possibility of applying small molecule RIPK2 inhibitors to anti-tumor therapy. Frontiers Media S.A. 2023-05-30 /pmc/articles/PMC10266216/ /pubmed/37324457 http://dx.doi.org/10.3389/fphar.2023.1192970 Text en Copyright © 2023 You, Wang, Chen and Jin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology You, Jieqiong Wang, Ying Chen, Haifeng Jin, Fang RIPK2: a promising target for cancer treatment |
title | RIPK2: a promising target for cancer treatment |
title_full | RIPK2: a promising target for cancer treatment |
title_fullStr | RIPK2: a promising target for cancer treatment |
title_full_unstemmed | RIPK2: a promising target for cancer treatment |
title_short | RIPK2: a promising target for cancer treatment |
title_sort | ripk2: a promising target for cancer treatment |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266216/ https://www.ncbi.nlm.nih.gov/pubmed/37324457 http://dx.doi.org/10.3389/fphar.2023.1192970 |
work_keys_str_mv | AT youjieqiong ripk2apromisingtargetforcancertreatment AT wangying ripk2apromisingtargetforcancertreatment AT chenhaifeng ripk2apromisingtargetforcancertreatment AT jinfang ripk2apromisingtargetforcancertreatment |